Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 4
2018 2
2019 3
2020 2
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Decreased incidence of acute immune thrombocytopenia in children during the COVID-19 pandemic.
Harama D, Goi K, Saito K, Sato H, Somazu S, Furuichi Y, Takahashi K, Oshiro H, Nakamura M, Sawanobori E, Sato K, Tsuruta M, Murakami Y, Shinohara T, Nemoto A, Kasai S, Tamai M, Watanabe A, Akahane K, Kojika S, Sugita K, Inukai T. Harama D, et al. Among authors: somazu s. Int J Hematol. 2023 Feb;117(2):307-308. doi: 10.1007/s12185-022-03521-7. Epub 2023 Jan 12. Int J Hematol. 2023. PMID: 36633776 Free PMC article. No abstract available.
CRISPR/Cas9-Mediated Induction of Relapse-Specific NT5C2 and PRPS1 Mutations Confers Thiopurine Resistance as a Relapsed Lymphoid Leukemia Model.
Nguyen TTT, Tanaka Y, Sanada M, Hosaka M, Tamai M, Kagami K, Komatsu C, Somazu S, Harama D, Kasai S, Watanabe A, Akahane K, Goi K, Inukai T. Nguyen TTT, et al. Among authors: somazu s. Mol Pharmacol. 2023 Apr;103(4):199-210. doi: 10.1124/molpharm.122.000546. Epub 2023 Jan 20. Mol Pharmacol. 2023. PMID: 36669880
NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S, Tanaka Y, Tamai M, Watanabe A, Kagami K, Abe M, Harama D, Shinohara T, Akahane K, Goi K, Sugita K, Moriyama T, Yang J, Goto H, Minegishi M, Iwamoto S, Takita J, Inukai T. Somazu S, et al. J Cell Mol Med. 2021 Nov;25(22):10521-10533. doi: 10.1111/jcmm.16981. Epub 2021 Oct 12. J Cell Mol Med. 2021. PMID: 34636169 Free PMC article.
High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.
Akahane K, Yasuda T, Tsuzuki S, Hayakawa F, Kiyokawa N, Somazu S, Watanabe A, Kagami K, Abe M, Harama D, Goi K, Kawazu M, Kojima S, Imamura T, Goto H, Iwamoto S, Minegishi M, Abe M, Hojo H, Inaba T, Mano H, Sugita K, Inukai T. Akahane K, et al. Among authors: somazu s. Hematol Oncol. 2020 Oct;38(4):614-617. doi: 10.1002/hon.2762. Epub 2020 Jun 24. Hematol Oncol. 2020. PMID: 32515032 No abstract available.
Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy.
Watanabe A, Inukai T, Kagami K, Abe M, Takagi M, Fukushima T, Fukushima H, Nanmoku T, Terui K, Ito T, Toki T, Ito E, Fujimura J, Goto H, Endo M, Look T, Kamps M, Minegishi M, Takita J, Inaba T, Takahashi H, Ohara A, Harama D, Shinohara T, Somazu S, Oshiro H, Akahane K, Goi K, Sugita K. Watanabe A, et al. Among authors: somazu s. Cancer Med. 2019 Sep;8(11):5274-5288. doi: 10.1002/cam4.2356. Epub 2019 Jul 15. Cancer Med. 2019. PMID: 31305009 Free PMC article.
Successful treatment of intractable gastrointestinal tract graft-vs-host disease with oral beclomethasone dipropionate in pediatric and young adult patients: Case reports.
Akahane K, Watanabe A, Somazu S, Harama D, Shinohara T, Kasai S, Oshiro H, Goi K, Hasuda N, Ozawa C, Sugita K, Inukai T. Akahane K, et al. Among authors: somazu s. Medicine (Baltimore). 2022 Mar 18;101(11):e29054. doi: 10.1097/MD.0000000000029054. Medicine (Baltimore). 2022. PMID: 35356922 Free PMC article.
Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Huang M, Inukai T, Miyake K, Tanaka Y, Kagami K, Abe M, Goto H, Minegishi M, Iwamoto S, Sugihara E, Watanabe A, Somazu S, Shinohara T, Oshiro H, Akahane K, Goi K, Sugita K. Huang M, et al. Among authors: somazu s. Cancer Med. 2018 Apr;7(4):1297-1316. doi: 10.1002/cam4.1323. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473342 Free PMC article.
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM, Nemoto A, Sato H, Huang M, Abe M, Kagami K, Shinohara T, Watanabe A, Somazu S, Oshiro H, Akahane K, Goi K, Kikuchi J, Furukawa Y, Goto H, Minegishi M, Iwamoto S, Sugita K. Takahashi K, et al. Among authors: somazu s. PLoS One. 2017 Dec 13;12(12):e0188680. doi: 10.1371/journal.pone.0188680. eCollection 2017. PLoS One. 2017. PMID: 29236701 Free PMC article.
Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines.
Tamai M, Huang M, Kagami K, Abe M, Somazu S, Shinohara T, Harama D, Watanabe A, Akahane K, Goi K, Sugita K, Goto H, Minegishi M, Iwamoto S, Inukai T. Tamai M, et al. Among authors: somazu s. Cancer Cell Int. 2020 Sep 4;20(1):434. doi: 10.1186/s12935-020-01524-0. Cancer Cell Int. 2020. PMID: 33499894 Free PMC article.
14 results